A ging is a potent and universal risk factor for cardiovascular diseases (CVD), including heart attack, stroke, and heart failure. 1 Mortality from CVD increases exponentially with age, accounting for >40% of deaths in people aged 65 to 74 years and 60% in those >85 years. 2 As previous antiaging therapies have shown only modest benefits in CVD, 3, 4 further understanding of the aging process is needed to identify effective treatments to prevent or reverse cardiovascular aging.
Increased vascular stiffness is a prominent consequence of the aging process. Although the presence of multiple CVD risk factors, particularly hypertension, may accelerate vascular stiffening, a previous study found that increased vascular stiffness precedes hypertension. 5 Pulse wave velocity (PWV) is a well-validated noninvasive measure of vascular stiffness, and substantial evidence supports that PWV significantly increases with age in humans and contributes to systolic hypertension. [6] [7] [8] Increased PWV with aging has been linked to structural changes in the vasculature, including increased collagen accumulation, reduced elastin content, and vascular calcification. 7 Vascular stiffening increases the workload required by the heart to maintain adequate blood flow and in this way may promote cardiac hypertrophy and fibrosis and ultimately contribute to the high incidence of heart failure with aging. 9, 10 Moreover, vascular stiffness is a strong predictor of future myocardial infarction, stroke, or CVD mortality independent of any other traditional CVD risk factors, including blood pressure (BP). 6, 8, 11 The renin-angiotensin-aldosterone system (RAAS) is a hormonal cascade that plays a critical role in BP regulation. Previous studies revealed that RAAS component expression and angiotensin signaling in the arterial wall increase with aging and contribute to vascular structural alterations. 2, 8, 12, 13 The terminal step of the RAAS is the activation of MRs (mineralocorticoid receptors) by the hormone aldosterone. MR is a hormone-activated transcription factor that modulates BP by regulating renal genes that promote sodium retention.
14 MR is also expressed in extrarenal cells, including vascular smooth muscle cells (SMC), endothelial cells (EC), cardiomyocytes, and macrophages, and substantial evidence from animal studies reveals that extrarenal MR contributes to CVD. 15 Similarly, in human clinical trials, MR antagonists significantly reduce Prior studies support that MR activation contributes to the regulation of vascular structure and that this may be mediated by direct effects on the vasculature. [18] [19] [20] In rodent models, MR antagonist drugs attenuate vascular stiffness and fibrosis in the setting of CVD risk factors despite minimal effects on BP. 21, 22 Also in humans with chronic MR activation because of primary aldosteronism, vascular stiffness is significantly increased compared with BP-matched hypertensive patients with normal aldosterone levels. 23 Moreover, in patients with hypertension, treatment with the MR antagonist eplerenone for 1 year significantly decreased vascular stiffness when compared with treatment to the same BP goal with a β-blocker. 24 These studies suggest that MR can contribute to vascular stiffness and fibrosis independent of renal effects to lower BP.
MR is expressed in human and mouse vascular SMC where it directly regulates vascular gene transcription and SMC function. 25, 26 Recent studies using mice with MR specifically knocked out (KO) from SMC (SMC-MR-KO) revealed that SMC-MR contributes to vascular remodeling and fibrosis in response to wire injury 20 and to vascular stiffening induced by the aldosterone/salt model of hypertension. 26 However, the role of SMC-MR in cardiovascular stiffening with aging has not been explored. MR expression has been shown to increase with aging in rat aortic SMC 27 and in mouse resistance vessels. 28 Also, aged SMC-MR-KO mice are protected from the modest rise in BP, enhanced vascular constriction, and oxidative stress observed in aged MR-intact littermates, 18 supporting a direct role for SMC-MR in the process of aging. Hence, the aim of this study was to characterize the role of SMC-MR in cardiovascular tissue stiffness, fibrosis, and vascular gene regulation in aging mice and to explore whether targeting MR would inhibit SMC-MR-driven pathways to attenuate vascular aging in mice and in humans. The life expectancy of C57BL6 mice in captivity is 24 to 36 months. Prior studies exploring the vascular aging phenotype demonstrate that endothelial stiffness increases from 3 to 15 months of age 29 and aortic SMC hypertrophy and expression of fibrosis genes increase from 3 to 12 months of age with a further increase by 24 months. 13, 30 Because these prior studies demonstrate vascular aging changes as early as at 12 months of age in mice, here we characterized the vascular and cardiac phenotype of SMC-MR-KO and MR-intact littermates at 12 and 18 months of age compared with 3-month-old controls. We further determined changes in the vascular gene expression profile at 12 months compared with 3 months of age to explore early aging effects on gene expression that might be causative and potentially modifiable by SMC-MR deletion or by treatment with an MR antagonist drug in mice and in humans.
Methods
Detailed methods are available in the online-only Data Supplement. Complete microarray data are available at National Center for Biotechnology Information Gene Expression Omnibus (accession number: GSE102397). All other data that support the findings of this study are available from the corresponding author on reasonable request.
Animals
All mice were handled in accordance with US National Institutes of Health standards, and all procedures were approved by the Tufts Medical Center Institutional Animal Care and Use Committee. Creation of tamoxifen-inducible SMC-MR-KO mice and confirmation of inducibility and specificity of SMC-MR recombination have been described previously. 18 Wild-type (WT) male mice (12-monthold) were implanted in the subscapular region with pellets containing either placebo or spironolactone (20 mg/kg per day) for 120 days.
Human Serum
Detailed protocol for collecting human serum is available in the online-only Data Supplement. All studies were approved by the institutional review board at all institutions involved.
Statistical Analysis
Values are presented as mean±SEM. Means were compared by 1-or 2-factor ANOVA as appropriate, with Tukey post hoc test using SigmaPlot statistical software. P<0.05 was considered significant.
Results

Deletion of MR in SMC Prevents Vascular Stiffness and Fibrosis With Aging
Vascular stiffness was measured by quantifying aortic PWV in male MR-intact and SMC-MR-KO littermates at 3, 12, and 18 months of age. PWV increased with aging from 3 to 12 months with a nonsignificant trend toward a further increase from 12 to 18 months of age (P=0.08) in MR-intact mice but not in SMC-MR-KO mice. Thus, SMC-MR-KO mice had significantly lower PWV at 12 and 18 months of age compared with agematched MR-intact mice ( Figure 1A ). Vascular fibrosis, a driver of vascular stiffness, was quantified in 3 different sized vessels: aorta, carotid artery, and renal arteriole. In MR-intact mice, vascular fibrosis increased with aging from 3 to 12 months in all 3 vascular beds ( Figure 1B-1D ). In the aorta, the vessel from which stiffness is measured by PWV, fibrosis was prevented in SMC-MR-KO ( Figure 1B) . In carotid arteries, fibrosis was decreased in SMC-MR-KO mice at 12 and 18 months relative to age-matched MR-intact mice ( Figure 1C ). Finally, in renal arterioles, fibrosis was attenuated in SMC-MR-KO at 18 months of age compared with age-matched MR-intact mice ( Figure 1D ). These results indicate that SMC-MR is necessary for aging-associated vascular stiffening and contributes to fibrosis in both conduit arteries and arterioles of aging mice.
SMC-MR Deletion Protects From Aging-Associated Cardiac Stiffness and Fibrosis
We next examined the effect of SMC-MR deletion on endorgan function in aging mice. Cardiac structure and function were assessed by cardiac ultrasound, in vivo hemodynamic measurements, and histology. With aging to 12 months in MR-intact mice, cardiac hypertrophy developed (increased left ventricular [LV] mass/tibia length), followed by chamber dilation at 18 months (increased LV end-systolic and end-diastolic diameter), in association with a modest but significant reduction in LV ejection fraction and fractional shortening at 18 months of age (Table S1 ). These significant aging-related changes in cardiac hypertrophy, dilation, and dysfunction did not occur in SMC-MR-KO mice. Invasive hemodynamic measures of intrinsic cardiac function (stroke volume, peak LV pressure change in systole, diastolic relaxation time) did not significantly change with aging in either genotype (Table S1 ). However, aging was associated with a significant increase in LV diastolic and systolic stiffness in MR-intact mice that was prevented in SMC-MR-KO mice, as assessed by the slope of the LV end-diastolic or -systolic pressure-volume relationship ( Figure 2A and 2B, respectively).
We next assessed cardiac fibrosis histologically ( Figure 2C  and 2D ). Both perivascular and interstitial fibrosis increased with aging in MR-intact mice while only interstitial fibrosis significantly increased with aging in SMC-MR-KO mice. Both perivascular and interstitial fibrosis were significantly attenuated in SMC-MR-KO at 12 and 18 months of age compared with agematched MR-intact mice, consistent with reduced cardiac stiffening with aging. The degree of systolic stiffness as measured by end-systolic pressure-volume relationship significantly correlated with aortic stiffness by PWV ( Figure 2E ) as did cardiac diastolic stiffness (end-diastolic pressure-volume relationship), but to a less extent (r=0.46; P=0.003; data not shown). Changes in kidney hypertrophy and fibrosis also increased significantly with age, but these renal changes were independent of the presence of SMC-MR ( Figure S1 ). Finally, although endurance exercise capacity decreased with aging in both MR-intact and SMC-MR-KO mice, the decline was attenuated such that 18-monthold SMC-MR-KO had significantly improved endurance exercise capacity compared with age-matched MR-intact mice ( Figure 2F ) with no difference in serum aldosterone, glucose, or cholesterol in aged MR-intact compared with SMC-MR-KO mice ( Figures S2 and S3 ). Combined, these results demonstrate that SMC-MR plays a role in aging-associated cardiac fibrosis and stiffening, without influencing renal fibrosis, thus the mechanism of fibrosis in renal aging may differ from that in the heart and vessels and is not dependent on SMC-MR. were assessed by invasive hemodynamic measurements. C, Perivascular and (D) interstitial fibrosis were quantified in left ventricle sections stained with Picrosirius red. Scale bar=50 μm. E, There is a significant correlation between cardiac stiffness (ESPVR) and vascular stiffness (PWV). F, Endurance exercise capacity was determined my measuring run to exhaustion time normalized to body mass and vertical distance. n=5 to 6 mice per group. *P<0.05 and **P<0.01 compared with genotype-matched 3-moold mice; †P<0.05 and ‡P<0.01 compared with age-matched MR-intact mice.
Distinct Vascular Aging Transcriptomes in the Presence or Absence of SMC-MR
Because MR is a transcriptional regulator, we next performed global aortic mRNA expression profiling to explore potential mechanisms by which SMC-MR deficiency protects from vascular aging. Microarray profiles from MR-intact and SMC-MR-KO littermates were compared in young 3-month-old mice and aged 12-month-old mice, the age at which SMC-MR dependent structural changes are first observed in Figure 1 . Four differential gene expression comparisons were performed to assess the role of SMC-MR and aging, and the numbers of up regulated or downregulated genes for each comparison are shown in Figure 3A . The complete list of all regulated genes can be found in Tables S2 to S5 . Expression of MR gene (Nr3c2) in the aorta increased significantly with aging and was decreased in aortas from SMC-MR-KO compared with aortas from MR-intact mice at each age. Microarray data were validated for selected genes by independent quantitative reverse transcription polymerase chain reaction in aortic RNA derived from a second cohort of mice. Overall, 86% of tested gene expression changes from the microarray study were reproduced by polymerase chain reaction in biological replicates (Table S6) . Compared with age-matched MR-intact mice, only 66 genes were differentially expressed in aortas from young SMC-MR-KO mice while 579 genes were differentially expressed in aortas from aged SMC-MR-KO mice ( Figure 3A ). This is consistent with the data in Figure 1 revealing minimal effects of SMC-MR deletion on vascular structure and function in young mice but substantial effects in aged mice.
Another approach to examining the role of SMC-MR in vascular aging is to contrast gene expression changes with aging in SMC-MR-KO with those with aging in MR-intact mice. Interestingly, although similar numbers of genes were differentially expressed with aging in MR-intact (552 genes) and SMC-MR-KO (477 genes) mice, only 79 genes changed significantly with aging in both MR-intact and SMC-MR-KO mice. Of these, only 2 genes, ubiquitin-conjugating enzyme E2 Q family like 1 (ube2ql1) and small nucleolar RNA C/D box 34 (snord34), were regulated in opposite directions with aging in the 2 genotypes ( Figure 3B ). These findings suggest that rather than merely preventing the expression of vascular agingassociated genes, the absence of SMC-MR results in recruitment of a distinct set of genes in the aging vasculature that are associated with protection from vascular stiffness and fibrosis.
Pathways Associated With Progression and Protection From Vascular Aging
To systemically understand the genes driving the vascular aging phenotype in MR-intact mice compared with the protective gene program recruited with aging in SMC-MR-KO mice, Ingenuity Pathway Analysis was performed. Cardiovascular system development and function was the top over-represented biological function category within the genes differentially expressed with aging in MR-intact mice (Table S8) . Within this category, there were 10 subcategories significantly regulated with aging in both MR-intact and SMC-MR-KO mice. Comparing the z-score, a measure of the predicted direction of regulation of these subcategories revealed that 8 of those 10 subcategories were predicted to be regulated in opposite directions with aging when comparing MR-intact and SMC-MR-KO mice ( Figure 4A ). Notably, this opposing regulation was not driven by opposite regulation of the same genes. Rather, a distinct gene signature was regulated with aging in MR-intact versus SMC-MR-KO littermates that coordinately results in opposing effects on these cardiovascular pathways. For example, FGF2 (fibroblast growth factor 2) was upregulated in MR-intact mice but unchanged in SMC-MR-KO mice with aging. Whereas, CTGF (connective tissue growth factor) was unchanged in MR-intact mice and downregulated in the aorta of SMC-MR-KO mice with aging. The gene signatures that contribute to opposing regulation of cardiovascular system development and function are indicated in Figure 4B . These results support the concept that the biological processes activated with aging in aortas from MR-intact mice are reversed in aortas from SMC-MR-KO mice by recruiting a distinct set of genes with opposing biological functions.
The top 5 Ingenuity Pathway Analysis gene networks differentially regulated with aging in MR-intact and SMC-MR-KO littermates are summarized in Table S9 . The top regulated gene network in SMC-MR-KO mice is made up of genes involved in connective tissue development and function ( Figure 4C ). Of 29 genes in this network, 23 genes were downregulated with aging. The remaining 6 were unchanged with aging. However, all 29 genes in this network were unchanged with aging in MR-intact mice (data not shown). This network is known to play a critical role in promoting tissue fibrosis, thus the profound downregulation of this pathway in aged vessels lacking SMC-MR supports recruitment of an antifibrotic gene program as a possible mechanism for the protection from vascular fibrosis with aging in SMC-MR-KO mice.
Upstream regulator analysis was used to identify regulators predicted to coordinately control the gene expression changes observed (Table S10) . Interestingly, the MR antagonist eplerenone was predicted to be inhibited with aging in MR-intact mice while the MR agonist aldosterone was predicted to be inhibited with aging in SMC-MR-KO mice, supporting a critical mechanistic role for MR signaling in driving global vascular gene expression changes with aging. The upstream regulator most substantially inhibited with aging in SMC-MR-KO mice is TGFβ1 (transforming growth factor β1) that has a well-established role in promoting vascular fibrosis.
MR Antagonism in Aged Mice Attenuates Vascular Stiffness and Fibrosis and Recruits the Antifibrotic Vascular Gene Program Associated With SMC-MR Deficiency
We next tested whether systemic MR inhibition with spironolactone could attenuate the vascular stiffness and fibrosis associated with aging via similar antifibrotic mechanisms. Twelve-month-old male WT mice with established vascular stiffness and fibrosis ( Figure 1 ) were randomized to 4 months of treatment with placebo or a dose of spironolactone previously shown to have no depressor effect on BP. 21 PWV significantly increased from 12 to 16 months of age in placebo-treated mice while this was prevented in spironolactone-treated mice, resulting in significantly lower PWV in 16-month-old spironolactone-treated mice ( Figure 5A ). As PWV was measured every 2 months in the same mice, we examined the change in PWV from the 12-month-old baseline in each mouse and determined that spironolactone treatment prevented the progression of vascular stiffness after 2 and 4 months of treatment ( Figure 5B ). The degree of aortic, carotid, and renal fibrosis was also significantly attenuated by spironolactone compared with placebo ( Figure 5C and 5D ). As expected, serum aldosterone levels increased with spironolactone treatment (Table  S11) , confirming effective MR blockade, and BP measured by tail cuff method was not affected at this dose of spironolactone ( Figure 5E ). Next, aortic mRNA expression was quantified for the protective gene expression signature previously identified in SMC-MR-KO mice. C-X-C chemokine receptor type 4 was significantly upregulated and BMP4 (bone morphogenetic protein 4) and TGFβ1 were significantly downregulated in the aortas from spironolactone-compared with placebo-treated mice ( Figure 5F ). As in the SMC-MR-KO mice ( Figure 4C ), collagen type 1 and 3 (Col1 and Col3, respectively) mRNA expression levels were not significantly changed after 4-month spironolactone treatment. Although not universal for all genes, overall spironolactone treatment induced a similar protective vascular gene expression signature as that observed with aging in SMC-MR-KO mice (compare Figure 4B to Figure 5F ). As expected, aortic MR gene (Nr3C2) expression was unchanged with spironolactone treatment. Overall, systemic MR inhibition prevented aging-associated increases in vascular stiffness and fibrosis in aged mice while inducing an antifibrotic vascular gene expression signature similar to that induced with aging in SMC-MR-KO mice.
MR Antagonism in Aged Humans Induces Changes in Circulating Biomarkers That Correlate With the Antifibrotic Vascular Gene Signature
Because SMC-MR deletion or systemic MR inhibition induced a protective vascular gene expression program in aged mouse vessels, we aimed to test whether MR inhibition could induce similar effects in humans. Because human vascular tissue cannot be routinely obtained, we assessed circulating levels of the secreted protein products of the vascular protective SMC-MR gene signature, as well as other known fibrotic biomarkers. These biomarkers were measured in serum collected from a small study of 11 healthy male subjects average age 63.6±2.1 years treated for 1 month with eplerenone and 1 month with placebo in a randomized crossover study design, as previously described. 31 In general, after 1 month of MR antagonism, circulating levels of secreted products of genes from the SMC-MR vascular protective signature were reduced in older male subjects (Table) . Specifically, after eplerenone treatment, the serum matrix metallopeptidase 2 (MMP2) level decreased significantly, there was a strong trend toward decreased serum BMP4 (50% decrease; P=0.068), and CTGF also tended to decrease although this was not statistically significant in this small cohort of patients. This pattern matched the protective gene signature identified with aging in SMC-MR-KO mice and was also similar to the aortic gene expression pattern after 4 months of spironolactone treatment in aged WT mice ( Figures 4B and 5F ). Circulating levels of procollagen type I C-terminal peptide and procollagen type III N-terminal propeptide, biomarkers respectively of collagen type 1 and 3 production, were not significantly altered by eplerenone treatment. This is consistent with results from mouse vessels in which vascular Col1 and Col3 gene expressions were unchanged with aging in SMC-MR-KO mice and with MR antagonism in aged WT mice (Table S5 ; Figure 5F ). The circulating level of C-telopeptide of type I collagen (ICTP), a biomarker of collagen degradation, was significantly decreased in humans after MR antagonist treatment. This is consistent with the eplerenone-induced decrease in circulating MMP2, a matrix protease that degrades collagen. As in the mice, the aldosterone level was increased after eplerenone treatment, confirming the effectiveness of MR blockade in these patients. This short duration of eplerenone treatment did not affect vascular stiffness as previously reported by measuring PWV in this cohort. 31 Similarly, the changes in circulating levels of biomarkers between eplerenone and placebo treatment did not significantly correlate with the minimal changes in PWV (Table S12) . Although this study is small, the data support that short-term systemic inhibition of MR produces an antifibrotic biomarker signature that correlates with the protective gene expression program induced with aging in SMC-MR-KO mice and with spironolactone treatment in aged mice.
Discussion
By comparing aging MR-intact mice to SMC-MR-KO littermates, we identified a critical role for SMC-MR in cardiovascular aging. Specifically, we found that (1) increased vascular stiffness and fibrosis with aging are mitigated when MR is specifically deleted from SMC in mice; (2) aging-associated increases in cardiac stiffness and fibrosis and the decline in exercise capacity are also mitigated in the absence of SMC-MR; (3) gene expression profiling in mouse aortas revealed that vascular aging is associated with induction of gene pathways associated with cardiovascular development while when SMC-MR is deleted, aging induces a distinct antifibrotic gene signature; (4) in aged mice, systemic inhibition of MR prevents the progression of vascular stiffness and fibrosis with induction of a similar antifibrotic pattern of aortic gene expression to that seen with SMC-MR deletion; (5) systemic inhibition of MR, but not SMC-MR deletion, prevented renal fibrosis, suggesting a role for non-SMC MR in renal fibrosis with aging; and finally (6) shortterm MR antagonist treatment in a small human cohort of older males produces an analogous antifibrotic serum biomarker signature. Overall, this study identifies MR in SMC as a mediator of cardiovascular aging and as a potential target to prevent the adverse consequences of vascular stiffness with aging. These data support the initiation of larger trials to test whether long-term treatment with MR antagonists in older humans could prevent the progression of vascular fibrosis and stiffness and potentially improve cardiovascular outcomes with aging.
Conduit vessel stiffness significantly increases with aging in humans and in rodents, thereby promoting resistance vessel dysfunction and contributing to the development of hypertension and to impaired regional blood flow. 7, 9 As a consequence, vascular stiffness is a significant independent risk factor for myocardial infarction, stroke, and CVD death. 6, 11 The RAAS contributes to vascular fibrosis and stiffness with aging, 2,12 but the underlying mechanisms have not been completely elucidated. Here, we demonstrate for the first time that SMC-MR contributes to aging-associated changes in vascular fibrosis and stiffness and that MR deletion in vascular smooth muscle is sufficient to inhibit vascular fibrosis related to aging. Prior studies have also implicated MR in myeloid cells in vascular dysfunction and fibrosis 32 although this has not been explored with aging. EC stiffness has also been shown to increase with aging, 29 and EC-MR has been implicated in vascular stiffness in response to obesity 19 by a mechanism implicating upregulation of epithelial sodium channels. 33, 34 Thus, MR in other cell types likely also contribute to vascular aging.
A role for SMC-MR was previously demonstrated in arterial stiffening and fibrotic remodeling in young mice in response to hypertension or to direct vascular injury. 20, 26 Notably, in both models, vascular structure was unchanged by deletion of MR in the absence of a vascular injury stimulus. Indeed, in uninjured carotid arteries, MR activation by aldosterone infusion did not affect vascular structure. 20 Combined with the current study, the data support the overall concept that SMC-MR does not modulate vascular structure in the healthy state but rather SMC-MR is a critical mediator of the vascular fibrotic response in the setting of vascular damage induced by direct injury, hypertension, and now also aging. Interestingly, the serum aldosterone level was significantly decreased in 18-month compared with 12-month-old mice regardless of the presence of SMC-MR. Prior studies show that MR can be activated in a ligand-independent manner by angiotensin II 25 and ras-related C3 botulinum toxin substrate 1. 35 Angiotensin II signaling is augmented with aging, 13 and ras-related C3 botulinum toxin substrate 1 is activated by oxidative stress, 36 which also increases with aging. This raises the possibility that other hormones or hormone-independent mechanism might activate vascular MR with aging.
It is well-known that cardiac structure also changes with age, resulting in wall thickening, fibrosis, and stiffness that contribute to heart failure with preserved ejection fraction and in some cases, ultimately leads to cardiac dilation and systolic dysfunction. 37 Ample data show that MR antagonist treatment reduces cardiac remodeling and mortality associated with heart failure and hypertension in animals and in humans. 16, 17, 21, 22 These benefits are generally independent of changes in BP and kidney function, yet the specific cell type in which MR inhibition is cardioprotective is only beginning to be elucidated. 15 Deletion of MR in cardiomyocytes (but not fibroblasts) in mice prevented cardiac dysfunction and remodeling in response to pressure overload or myocardial infarction, and MR deletion in macrophages prevented cardiac fibrosis in response to deoxycorticosterone/salt hypertension. 15 In the current study, the aging-associated increase in cardiac fibrosis is attenuated by SMC-MR deletion. Several potential mechanisms could contribute to the role of SMC-MR in aging-induced cardiac fibrosis. First, increased aortic stiffness exposes to the heart to higher pressures, and this can lead to LV hypertrophy, fibrosis, and systolic stiffening. 9, 10 Indeed, the degree of cardiac systolic stiffness correlated with the degree of vascular stiffness, so perhaps the cardiac benefits in SMC-MR-KO mice are secondary to the prevention of vascular stiffening. Another potential mechanism could involve a role for SMC-MR in leukocyte extravasation into the heart. Extracellular matrix stiffening has been shown to enhance leukocyte extravasation, 38 and secreted factors induced by MR in SMC have been shown to recruit leukocytes in vitro. 39 MR in EC has also been shown to play a role in leukocyte recruitment, adhesion, and transmigration through the endothelium. 40 However, specific deletion of MR from EC in a mouse model protected from cardiac dysfunction in response to pressure overload without affecting cardiac leukocyte infiltration. 41 Indeed, it was previously demonstrated that MR inhibition prevents angiotensin II/salt-induced cardiac perivascular inflammation and fibrosis in rats although the cell-specific role of MR was not addressed. 42 SMC-MR in coronary arteries may contribute to leukocyte infiltration that drives perivascular fibrosis, limiting oxygen delivery, thereby damaging cardiomyocytes and contributing to interstitial fibrosis. Alternatively, or in addition, SMC-MR may contribute to vasoconstriction in coronary vessels and in this way lead to cardiac ischemia and fibrosis with aging. A prior study demonstrated a role for SMC-MR in coronary vasoconstriction in response to ischemia-reperfusion in the heart. 43 Overall, the current study demonstrates a role for SMC-MR in cardiac remodeling with aging, and further studies are warranted to differentiate between these potential mechanisms.
Exercise capacity decreases with aging in humans, is a powerful predictor of mortality, and contributes to declining quality of life. 44, 45 In the current study, we confirmed that exercise capacity decreases with aging in mice, and this decline is mitigated in SMC-MR-KO mice. There are many physiological factors involved in determining exercise capacity, including pulmonary diffusion, cardiac output, vascular function, oxygen carrying in the blood, skeletal muscle blood flow, and energy metabolism, all factors that are compromised with aging. 44 Some studies suggest that MR may regulate energy metabolism, potentially via MR in adipocytes, 46 but there is no evidence that this is affected by SMC-MR as growth and glucose were unchanged in knockout mice although metabolic function was not formally tested. Given the notion that a critical limiting factor for exercise capacity is oxygen delivery to exercising muscles in response to increasing physiological demands, 45 reduced fibrosis and stiffness in the heart and vessels of old SMC-MR-KO mice could contribute to increased oxygen delivery to exercising muscles. Further studies are needed to directly test the role of SMC-MR in regulating skeletal muscle blood flow in response to exercise and how this might change with aging.
Because MR is a hormone-activated transcription factor, we compared the vascular aging transcriptomes in the presence and absence of SMC-MR in 12-month-old mice to identify early mechanisms driving the protection from vascular aging. Because the mouse aorta is largely composed of SMC, 47 gene expression profiles from aortas predominantly represent SMC gene expression. Rammos et al 48 previously reported that 561 genes were differentially regulated with aging in aortas from C57BL/6 mice. These genes were enriched in signaling pathways, including extracellular matrix integrity, chemokine signaling, cell adhesion, as well as the RAAS, thus our findings are consistent with prior studies. Importantly, rather than merely shutting down the genes recruited with aging in MR-intact vessels, SMC-MR deletion produced a distinct gene expression pattern with aging. MR deletion resulted in profound downregulation of BMP4, CTGF, and TGFβ1, well-characterized profibrotic regulators that contribute to vascular fibrosis with aging. 9 These genes were unchanged with aging in MR-intact mice, supporting that MR activation in SMC is driving the consistent expression of these profibrotic genes in the vasculature over time. Several mechanisms have been identified by which vascular MR regulates gene expression, including direct binding to MR-responsive elements in gene promoter, 49 regulation of other transcriptional factors, such as AP-1 (activator protein 1) and NF-kB (nuclear factor-κB) in the heart, 50 and epigenetic mechanisms including suppression of miR-155 expression in SMC. 28 Because these mechanisms are cell, tissue, or gene specific, further studies are required to unravel the mechanisms by which SMC-MR globally regulates fibrotic vascular gene expression with aging.
MR antagonism was previously shown to prevent the development of vascular stiffness and fibrosis induced by hypertension or aging in animal models, 21 ,22 so we explored the therapeutic potential of systemic MR inhibition to induce a similar antifibrotic phenotype in aged mice using a low dose of spironolactone that did not reduce BP in a prior study. 21 A direct effect of spironolactone on the vasculature is supported by demonstration that MR antagonism induced similar aortic gene expression changes as those in aging SMC-MR-KO mice. Specifically, TGFβ1 and BMP4 were significantly downregulated by spironolactone treatment, and these genes are known to play a role in SMC proliferation, hypertrophy, calcification, and matrix remodeling, which together contribute to fibrosis. 9 In addition, CTGF is a critical mediator of fibrosis and a known vascular MR target gene. 51 Together, these findings support the idea that increased SMC-MR expression and signaling with aging alter vascular gene expression and directly contribute to vascular structural changes and that MR inhibition prevents this process and the associated cardiovascular dysfunction. Interestingly, renal fibrosis is also inhibited by global MR inhibition but not by SMC-MR deletion, suggesting that MR in non-SMC mediated the protective effect of spironolactone on kidney fibrosis with aging.
To explore the translational implications of these preclinical studies, we measured serum circulating levels of SMC-MR target genes and known fibrosis biomarkers in a small cohort of elderly males after 1 month of eplerenone treatment. Biomarkers were measured as surrogates because vascular gene expression could not be directly assessed in human vessels. Eplerenone reduced circulating levels of MMP2 and ICTP with a trend toward a decrease in BMP4 and CTGF (49% decrease, P=0.068 and 37% decrease, P=0.15, respectively). This overall pattern of circulating biomarkers in response to eplerenone mirrors the aortic gene expression signature in aging SMC-MR-KO and spironolactone-treated aged WT mice. Changes in collagen turnover biomarkers have been associated with adverse CVD outcomes, including heart failure and atherosclerosis. 52, 53 Because ICTP is an MMP-dependent degradation product of type I collagen, 53 the decreased level of MMP2 with eplerenone treatment could contribute to the decrease in ICTP level induced by MR inhibition. A previous clinical study showed that the serum ICTP levels positively correlate with arterial stiffness. 54 Although there was no change in PWV with MR inhibition in our clinical study, this might be expected because of the short-term (1 month) treatment. Indeed, this is consistent with our mouse study in which 2-month spironolactone treatment in aged mice did not significantly affect vascular stiffness, yet vascular stiffness was significantly decreased after 4 months of treatment. It remains possible that the observed changes in serum fibrosis biomarkers in our small human study reflect early changes in vascular gene expression that could lead to improvements in vascular function and structure with longer duration of treatment. These results support the need for larger and longer clinical studies to clarify the potential benefits of MR antagonism to treat vascular stiffness and associated morbidity with aging.
Some limitations and future directions should be acknowledged. (1) Spironolactone or eplerenone globally antagonizes MR, thus the changes observed with MR antagonist treatment may be driven by inhibition of SMC-MR and MR in other cell types. A recent study reported that EC-specific deletion of MR in female mice prevented vascular remodeling and stiffness induced by obesity. 19 Because SMC and EC function in concert to regulate vascular function and structure, 55 globally blocking both SMC-and EC-MR in the vasculature by MR antagonist might contribute concomitantly to the observed changes in vascular fibrosis and stiffness. Accordingly, future studies are needed to explore the specific role of EC-MR in vascular aging. Because MR antagonists have a small but concerning risk of hyperkalemia through MR inhibition in the kidney, 17 this study supports further development of vascular-specific drug delivery platforms. (2) BP was measured by the less sensitive method of tail cuff plethysmography in the spironolactone study so as to not disturb aortic structure with a telemetry catheter to allow for accurate PWV and fibrosis measurements. Because this method would not be sensitive to small changes in BP, we cannot rule out the possibility that spironolactone resulted in a small difference in BP that is below the level of detection of this otherwise well-validated tail cuff method. (3) Previous studies have shown that SMC-MR contributes to vascular calcification 56 and to oxidative stress with aging 18, 28 ; however, there are other important processes that contribute to vascular aging, including mitochondrial dysfunction, autophagy, DNA damage, and cell senescence. 57 Although beyond the scope of this study, it would be interesting to determine whether SMC-MR contributes to these additional aging mechanisms in the vasculature. (4) Finally, for practical reasons, only male mice were used in this long-term aging study. Substantial evidence indicates sex differences in vascular aging, 58 and recent studies suggest a potential sex-specific contribution of MR to other aspects of vascular function. 19, 59 Accordingly, future studies are warranted to examine sex difference in the role of SMC-MR in vascular aging.
Perspectives
This study reveals that MR in smooth muscle cells plays a critical role in vascular stiffness and fibrosis with aging. Moreover, deletion of MR specifically from SMC attenuates cardiac stiffening and fibrosis and recruits a potent antifibrotic vascular gene expression program with aging. Results from both aged mice and humans treated with an MR antagonist suggest that MR antagonism may prevent the progression of aging-associated vascular stiffness by inhibiting SMC-MRdriven fibrosis pathways and support the possibility of using fibrosis biomarkers to monitor therapy. These data support the initiation of large long-term clinical studies of MR antagonists to determine potential vascular benefits that could mitigate cardiovascular aging and the associated cardiovascular morbidity and mortality that is so common in the elderly.
